Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S566000
Reexamination Certificate
active
07977379
ABSTRACT:
The present invention relates to a composition for use in prevention or treatment of a vascular-related disease, particularly used for angiogenesis inhibition, tumor growth inhibition or tumor metastasis inhibition, or immunostimulation, which comprises glutamic acid or derivatives thereof, preferably glutamic acid is anhydrous glutamic acid represented by Formula (1) or pyroglutamic acid, and a pharmaceutically acceptable carrier or an edible carrier, and a method of preventing or treating a vascular-related disease.
REFERENCES:
patent: 4975422 (1990-12-01), Kanoh et al.
patent: 4986982 (1991-01-01), Scott
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 6221910 (2001-04-01), Montner
patent: 6391332 (2002-05-01), Somerville et al.
patent: 6407066 (2002-06-01), Dressen et al.
patent: 6465218 (2002-10-01), Horiuchi et al.
patent: 6977311 (2005-12-01), Kochat et al.
patent: 2002/0169202 (2002-11-01), Sakamoto et al.
patent: 2003/0064484 (2003-04-01), Horiuchi et al.
patent: 2003/0068329 (2003-04-01), Kosuna et al.
patent: 2004/0248967 (2004-12-01), Sakamoto et al.
patent: 2009/0004247 (2009-01-01), Kosuna et al.
patent: 2 341 800 (2000-03-01), None
patent: 58131978 (1983-08-01), None
patent: H6-62413 (1987-03-01), None
patent: 63-119500 (1988-05-01), None
patent: 10-147534 (1988-06-01), None
patent: 6-62426 (1991-04-01), None
patent: 08-2666246 (1996-10-01), None
patent: 10-287584 (1998-10-01), None
patent: 10-298099 (1999-11-01), None
patent: 2000-159682 (2000-06-01), None
patent: 3071068 (2000-07-01), None
patent: 3120187 (2000-12-01), None
patent: 2001-240603 (2001-09-01), None
patent: 2001-269163 (2001-10-01), None
patent: 2001-333731 (2001-12-01), None
patent: 2002-065206 (2002-03-01), None
patent: 2002-220335 (2002-08-01), None
patent: 2004-018483 (2004-01-01), None
patent: WO 01/44488 (2001-06-01), None
Kim et al. Bioresource Tecnology 89 (2003) 81-87.
Grever et al., Seminars in Oncology, 19(6), 1992, pp. 622-638, especially pp. 626-627).
www.musclemaster.net/beverly-mass-amino.html (Mar. 2003).
Kahner et al. Phytochemistry, 49(6) 1693-1697, 1998.
Ann Rheum Dis 2001;60:iii71-iii74.
kahlon et al. Can J Cardiol. Jan.-Feb. 1992;8(1):60-4.
Takaku et al. J. Nutrition 131:1409-1413, 2001.
Life Extension Magazine (1999) 1-9.
Dunitz et al. (1995) Acta Cryst C51: 1377 1379.
Toth et al. Cancer research, 1978 V38 (1) p. 177-80.
U.S. Department of Health and Human Services, U.S. Food and Drug aAdministration, FDA Backgrounder, Aug. 31, 1995.
Hagenbart S. L. Food Product Design: Applications-Alternative Enhancers found at www.foodproductdesign.com, Feb. 1998.
Yoshiaki et al Nippon Shokuhin Kagaku Kaishi vol. 45(4) 246-252, 1998.
Twardzik et al Proc. Nat. Acad. Sci. USA vol. 69(1) p. 274 (abstract), 1972.
Answers.com (definition of prevention), 2005.
Zest for life-www.anyvitamins.com (1999-2003).
Maity et al (1999) Pathology Oncology Research V5(4)309-314.
Ng T.B. A review of research on protein-bound polysaccharide (polysaccharopeptide PSP) from the mushroomCoriolus versicolor(basidiomycetes: polyporaceae) Gen. Pharm. vol. 30 (1) p. 1-4 (1998).
Younan A, Sidky et al, Cancer Research, 47, p. 5155-5161, Oct. 1, 1987.
Shuichi Mizuno et al., Wakan Iyakugaku Zasshi, 15, p. 334-335.
Yoshiaki Fujimiya et al, Nippon Shokuhin Kagaku Kogaku Kaishi, vol. 45, No. 4, p. 246-252, Apr. 1998.
J. Kollonitsch et al, Chemistry and Industry, No. 7, p. 1867, Nov. 7, 1964.
Antonino Passaniti et al, Laboratory Investigation, vol. 67, No. 4, p. 519-528, 1992.
Antonio Passaniti, et al., Methods in Laboratory Investigation, A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor, Laboratory Investigation, vol. 67, No. 4, p. 519, 1992.
Notice of Reasons for Rejection for patent application No. 2003-131997 Dispatch No. 118514, Dispatch Date: Feb. 23, 2010.
Patent Abstracts of Japan, JP 2002-065206, May 2002.
Patent Abstracts of Japan, JP 2000-159682, Mar. 2000.
Patent Abstracts of Japan, JP 2001-269163, Feb. 2001.
Patent Abstracts of Japan, JP 10-298099, Nov. 1998.
Patent Abstracts of Japan, JP 2001-333731, Dec. 2001.
Patent Abstracts of Japan, JP 2001-240603, Sep. 2001.
Patent Abstracts of Japan, JP 08-266246, Oct. 1996.
Patent Abstracts of Japan, JP 10-287584, Oct. 1998.
Dispatch No. 761478, Dispatch Date—Nov. 17, 2009 “Notice of Reasons for Rejection” with English translation for Parent Patent Application No. 2003-13601 (6 pages).
Machine translation for JP 2002-220335 (abstract only), Aug. 2002.
Machine translation for JP 2004-018483, Jan. 2004.
Search Report from Companion Taiwanese case Application No. 092113214 (1 page).
Office Action issued in companion Taiwanese case Application No. 092113214 with English translation (8 pages).
Ishihara Keno
Kouge Takashi
Yamashita Akihiro
BHN Co., Ltd.
Conte James B.
Fetterolf Brandon J
Gembeh Shirley V
Husch & Blackwell LLP
LandOfFree
Method for angiogenesis inhibition or immunostimulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for angiogenesis inhibition or immunostimulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for angiogenesis inhibition or immunostimulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2688895